Interferon alpha kinoid

Drug Profile

Interferon alpha kinoid

Alternative Names: Antiferon; IFN-K - Neovacs; IFNα kinoid

Latest Information Update: 13 Feb 2017

Price : $50

At a glance

  • Originator Neovacs
  • Developer Neovacs; sanofi pasteur
  • Class Interferons; Vaccines
  • Mechanism of Action Immunomodulators; Interferon alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Systemic lupus erythematosus
  • New Molecular Entity Yes
  • Available For Licensing Yes - Systemic lupus erythematosus

Highest Development Phases

  • Phase II Dermatomyositis; Systemic lupus erythematosus
  • Preclinical Type 1 diabetes mellitus
  • Discontinued HIV infections; Sjogren's syndrome

Most Recent Events

  • 09 Feb 2017 Neovacs has patent protection for Interferon alpha kinoid in China, with pending applications in major markets worldwide
  • 03 Feb 2017 NeoVacs receives positive opinion from the Independent Data and Safety Monitoring Board for phase IIb trial in Systemic lupus erythematosus
  • 25 Jan 2017 NeoVacs plans a clinical trial for Type-I diabetes mellitus
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top